Thera-SAbDab

OLENDALIZUMAB

>   Structural Summary
TherapeuticOlendalizumab
TargetC5
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYTFTDYSMDWVRQAPGQGLEWMGAIHLNTGYTNYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARGFYDGYSPMDYWGQGTTVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCRASESVDSYGNSFMHWYQQKPGKAPKLLIYRASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPYTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2015
INN Year Recommended2017
Companies InvolvedAlexion Pharmaceuticals
Conditions Approvedna
Conditions ActiveAntiphospholipid syndrome, Graft-versus-host disease
Conditions DiscontinuedInflammation
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]